Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Medizinische Hochschule Hannover patents


Recent patent applications related to Medizinische Hochschule Hannover. Medizinische Hochschule Hannover is listed as an Agent/Assignee. Note: Medizinische Hochschule Hannover may have other listings under different names/spellings. We're not affiliated with Medizinische Hochschule Hannover, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medizinische Hochschule Hannover-related inventors


Methods and means for diagnosing spondylarthritis using autoantibody markers

The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (spa), in particular, of ankylosing spondylitis (as) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diaposis of the presence or the risk of development, or for the therapy control of spa, like as and undifferentiated spondyloarthritis, in a subject. ... Medizinische Hochschule Hannover

Methods and compositions for diagnosis of inflammatory liver disease

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (e3) levels, either alone or with levels of eotaxin-1 (e1), and optionally, with levels of ccl22 and, further optionally, with levels of il15. ... Medizinische Hochschule Hannover

Analysis for atherosclerosis

The invention provides a process for analysis of the presence of atherosclerosis in a patient sample, and preferably identifies a form of atherosclerosis that correlates to an increased risk of the patient to develop rheumatoid arthritis (ra), connective tissue diseases, vasculitis, and/or spondyloarthritis, and/or myocardial infarction and/or apoplexy.. . ... Medizinische Hochschule Hannover

Method for producing a fibrin-based bioartificial, primarily acellular construct, and the construct itself

The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.. ... Medizinische Hochschule Hannover

Anti-tumor medicament based on adenovirus

The invention provides manipulated adenovirus, i.e. A viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. ... Medizinische Hochschule Hannover

Surgical guidance device and method for its preparation

The invention is related to a surgical device for patient-specific guidance of at least one tool used during a surgical intervention, comprising at least the following features: a) at least one carrier system which is arranged for fixation on a bone structure of a patient, b) at least one guiding system connectable to the carrier system, the at least one guiding system comprising at least one base module and at least one guiding part for precisely defined guidance of at least one tool used during the surgical intervention, c) at least one connecting means for establishing a mechanical connection between the at least one guiding part and the at least one base module, wherein the connecting means comprises at least a non-fixed operating state and a fixed operating state, wherein in the non-fixed operating state the at least one guiding part can be adjusted relative to the base module in a patient-specific adjustment and in the fixed operating state the at least one guiding part is mechanically fixated relative to the at least one base module in the patient-specific adjustment, d) at least one mechanical interface for connecting the carrier system to the guiding system, comprising first interface means of the carrier system and second interface means of the guiding system, wherein the first interface means can be connected via form fit with the second interface means, thereby ensuring a defined adjustment of the guiding system relative to the carrier system by means of form fit. The invention is further related to a method for preparation of such a surgical guidance device.. ... Medizinische Hochschule Hannover

Method for preparing a biological tissue construct and use of autologous cells obtained specifically

The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (epc) which have not been passaged multiple times and have a content of eoec (early outgrowth endothelial progenitor cells) and loec (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. ... Medizinische Hochschule Hannover

A circulating non-coding rna as predictor of mortality in patients with acute kidney injury

The present invention relates to a a method for predicting mortality of a test patient with acute kidney injury comprising (a) detecting the expression level of the non-coding rna (ncrna) of seq id no: 1 in a sample obtained from said test patient with acute kidney injury, (b) comparing said expression level of the ncrna with the expression level of this ncrna in a sample obtained from control patients with acute kidney injury or with a predetermined standard expression level of this ncrna which was obtained on the basis of a sample from control patients with acute kidney injury, wherein the control patients were alive at least about 4 weeks after diagnosis of the acute kidney injury, and a greater than 1.5-fold overexpression of the ncrna in the test patient's sample as compared to the control patient's sample or as compared to the predetermined standard is indicative of an enhanced likelihood for future death of the test patient due to renal failure; and/or (b′) comparing said expression level of the ncrna with the expression level of this ncrna in a sample obtained from control patients with acute kidney injury or with a predetermined standard expression level of this ncrna which was obtained on the basis of a sample from control patients with acute kidney injury, wherein the control patients died from renal failure within about 4 weeks after diagnosis of acute kidney injury, and a greater than 1.5-fold underexpression of at the ncrna in the test patient's sample as compared to the control patient's sample or as compared to the predetermined standard is indicative of an enhanced likelihood for the long term survival of the test patient; and/or (b″) comparing said expression level of the ncrna with the expression level of the ncrna in a sample obtained from a healthy subject or with a predetermined standard expression level of this ncrna which was obtained on the basis of at least one sample from a healthy subject, wherein a greater than 5-fold overexpression of the ncrna in the test patient's sample as compared to the healthy sample or as compared to the predetermined standard is indicative of an enhanced likelihood for future death of the test patient due to renal failure.. . ... Medizinische Hochschule Hannover

Method for manufacturing a component by a generative manufacturing process, apparatus for manufacturing a component by a generative manufacturing process, and medical implant generated for an individual patient

The invention relates to a method for manufacturing a component (10) by a generative manufacturing process, wherein the component is entirely or partially produced from a liquid raw material (12), characterised in that the component is entirely or partially produced from a liquid raw material (12) that can solidify when heated, the raw material is discharged in liquid form into a manufacturing zone (1) and heated and hence solidified by a computer-controlled, targeted light spot, in that the point of incidence of a light beam (8) from a light beam source is continuously and/or gradually modified relative to the manufacturing zone (1).. . ... Medizinische Hochschule Hannover

Lncrnas for therapy and diagnosis of cardiac hypertrophy

The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding rnas (lncrnas) selected from seq id nos 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncrnas selected from seq id nos 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncrnas selected from seq id nos 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncrnas selected from seq id nos 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.. ... Medizinische Hochschule Hannover

Mutation for type i diabetes mellitus and animal model

The invention relates to a mutation in the dock8 encoding gene that is causative for type 1 diabetes mellitus at least in the rat (rattus norvegicus) or mouse, the rat or mouse preferably having an mhc predisposing towards type 1 diabetes mellitus and/or a mutation in the von willebrand factor vwa2. Embodiments of the invention comprise a process for generating a non-human mammal by genetic manipulation to contain at least heterozygously, preferably homozygously, the mutation causative for type 1 diabetes mellitus, preferably in combination with an mhc predisposing for type 1 diabetes mellitus and/or with a mutation in the von willebrand factor vwa2.. ... Medizinische Hochschule Hannover

Methods and compositions for diagnosis of inflammatory liver disease

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (e3) levels, either alone or with levels of eotaxin-1 (e1), and optionally, with levels of ccl22 and, further optionally, with levels of il15. ... Medizinische Hochschule Hannover

Medical implant, medical device and method for making a medical implant

The present invention relates to a medical implant which is vacuum-packed within an air tight cover material. Further, the present invention relates to a medical device for making a medical implant covered by an air tight cover material, wherein the medical device comprises at least an underpressure generating device and a sealing device, wherein the sealing device is arranged for air tight sealing of the cover material while the medical implant is located within the cover material, wherein the underpressure generating device is coupled or can be coupled with a space which is surrounded by the cover material, and wherein the underpressure generating device and the sealing device are controllable such that after generating a certain underpressure within the space surrounded by the cover material through the underpressure generating device the sealing device is activatable to seal the cover material in an air tight manner to form an air tight protection cover around the medical implant located therein. ... Medizinische Hochschule Hannover

Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity

The present invention relates to in vitro methods for producing neisseria meningitidis capsular polysaccharides which have a defined length. The present invention also relates to compositions comprising at least one capsule polymerase, at least one donor carbohydrate and at least one acceptor carbohydrate, wherein the ratio of donor carbohydrate to acceptor carbohydrate is a ratio from 10:1 to 400:1. ... Medizinische Hochschule Hannover

02/09/17 / #20170037405

Incrnas for therapy and diagnosis of angiogenesis

The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding rnas (lncrnas) selected from seq id nos 1 to 22, preferably selected from seq id nos 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncrnas selected from seq id nos 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncrnas selected from seq id nos 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding rnas (lncrnas) selected from seq id nos 1 to 22, preferably selected from seq id nos 1 to 3.. ... Medizinische Hochschule Hannover








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Medizinische Hochschule Hannover in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medizinische Hochschule Hannover with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###